Somatic rearrangements of transcription factors are common abnormalities in the acute leukemias. With rare exception, however, the resultant protein products have remained largely intractable as pharmacologic targets. One example is AML1-ETO, the most common translocation reported in acute myeloid leukemia (AML). To identify AML1-ETO modulators, we screened a small molecule library using a chemical genomic approach. Gene expression signatures were used as surrogates for the expression versus loss of the translocation in AML1-ETO-expressing cells. The top classes of compounds that scored in this screen were corticosteroids and dihydrofolate reductase (DHFR) inhibitors. In addition to modulating theAML1-ETOsignature, both classes induced evidence of differentiation, dramatically inhibited cell viability, and ultimately induced apoptosis via ontarget activity. Furthermore, AML1-ETO-expressing cell lines were exquisitely sensitive to the effects of corticosteroids on cellular viability compared with nonexpressers. The corticosteroids diminished AML1-ETO protein in AML cells in a proteasome- and glucocorticoid receptor-dependent manner. Moreover, these molecule classes demonstrated synergy in combination with standard AML chemotherapy agents and activity in an orthotopic model of AML1-ETO-positive AML. This work suggests a role for DHFR inhibitors and corticosteroids in treating patients with AML1-ETO-positive disease.

Identification of AML1-ETO modulators by chemical genomics / Roti, G; Corsello, Sm; Ross, Kn; Chow, Kt; Galinsky, I; Deangelo, Dj; Stone, Rm; Kung, Al; Golub, Tr; Stegmaier, K.. - In: BLOOD. - ISSN 0006-4971. - 113:24(2009), pp. 6193-6205. [10.1182/blood-2008-07-166090]

Identification of AML1-ETO modulators by chemical genomics.

Roti G;
2009

Abstract

Somatic rearrangements of transcription factors are common abnormalities in the acute leukemias. With rare exception, however, the resultant protein products have remained largely intractable as pharmacologic targets. One example is AML1-ETO, the most common translocation reported in acute myeloid leukemia (AML). To identify AML1-ETO modulators, we screened a small molecule library using a chemical genomic approach. Gene expression signatures were used as surrogates for the expression versus loss of the translocation in AML1-ETO-expressing cells. The top classes of compounds that scored in this screen were corticosteroids and dihydrofolate reductase (DHFR) inhibitors. In addition to modulating theAML1-ETOsignature, both classes induced evidence of differentiation, dramatically inhibited cell viability, and ultimately induced apoptosis via ontarget activity. Furthermore, AML1-ETO-expressing cell lines were exquisitely sensitive to the effects of corticosteroids on cellular viability compared with nonexpressers. The corticosteroids diminished AML1-ETO protein in AML cells in a proteasome- and glucocorticoid receptor-dependent manner. Moreover, these molecule classes demonstrated synergy in combination with standard AML chemotherapy agents and activity in an orthotopic model of AML1-ETO-positive AML. This work suggests a role for DHFR inhibitors and corticosteroids in treating patients with AML1-ETO-positive disease.
Identification of AML1-ETO modulators by chemical genomics / Roti, G; Corsello, Sm; Ross, Kn; Chow, Kt; Galinsky, I; Deangelo, Dj; Stone, Rm; Kung, Al; Golub, Tr; Stegmaier, K.. - In: BLOOD. - ISSN 0006-4971. - 113:24(2009), pp. 6193-6205. [10.1182/blood-2008-07-166090]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11381/2854144
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 32
social impact